A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Phase 2 – studying effectiveness and dosage
Conditions:
Myotonic Dystrophy Type 1 (DM1)
Sponsor: Vertex Pharmaceuticals Incorporated
trial.available_in:
БГ
Overview
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Who can participate
Key Inclusion Criteria:
• Completed study drug treatment in parent study VX23-670-001 (NCT06185764)
Key Exclusion Criteria:
• History of any illness or any clinical condition as pre-specified in the protocol
Other protocol defined Inclusion/Exclusion criteria may apply.
БГ